PTCHF — PureTech Health plc

—
OTC · Health Care · Pharmaceuticals · CIK 1782999 ·
Last close
$1.65
Market Cap
$405.77M
52W High
$1.92
52W Low
$1.45
ADV30
1,903
Next earnings
2026-09-22

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 — — — — 637,278,000 121,275,000 257,789,000
Dec 2025 — — — — 534,710,000 252,470,000 229,034,000
Jun 2025 — — — — 553,242,000 260,604,000 184,217,000

Balance + Analyst (yfinance extras)

Retained Earnings
$-9,983,000
Inventory
—
Receivables
—
ST Investments
$100,087,000
EBIT TTM
—
Pretax Income TTM
—
Interest Exp TTM
—
Analysts
—

Yahoo Snapshot (yfinance, live)

Total Revenue
$4,659,000
EBITDA
$-96,830,000
Free Cash Flow
$-89,990,376
Enterprise Value
$309,904,736
Total Cash
$288,716,000
Total Debt
$203,256,000
Shares Out
245,179,646
Trailing EPS
$-0.46
Book Value
$1.29
ROE
-30.9%
ROA
-10.8%
Div Yield
—

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 4,659,000 -98,525,000 -109,739,000 534,710,000 229,034,000 312,073,000 -85,131,000
Dec 2024 4,315,000 -136,095,000 53,510,000 602,635,000 194,702,000 414,707,000 -134,369,000
Dec 2023 750,000 -146,201,000 -65,697,000 693,973,000 235,742,000 464,066,000 -105,917,000
Dec 2022 2,090,000 -197,806,000 -50,354,000 702,647,000 155,058,000 542,220,000 -178,792,000

Peers — same industry

TickerNameMarket CapLastDaily %
AVTX Avalo Therapeutics, Inc. $412.28M $7.13 —
ELTP ELITE PHARMACEUTICALS INC /NV/ $397.36M $0.37 —
OCS Oculis Holding AG $417.01M $7.51 —
OVID Ovid Therapeutics Inc. $418.98M $2.22 —
IRD Opus Genetics, Inc. $391.45M $4.05 —

News headlines (Yahoo Finance, 1h cache)

PureTech Health PLC (PTCHF) (H1 2026) Earnings Call Highlights: Cash Runway to 2028, Seaport's ...
2026-09-22 19:00 · Yahoo
PureTech Health Wins 2026 Prix Galien USA Award in Incubators, Accelerators and Equity Category
2026-10-30 07:00 · Yahoo
PureTech Founded Entity Celea Therapeutics Appoints Paul Audhya, MD, MBA, as Chief Medical Officer
2026-10-29 11:01 · Yahoo
Celea Therapeutics Appoints Paul Audhya, MD, MBA, as Chief Medical Officer
2026-10-29 11:00 · Yahoo
PureTech Presents Phase 1b Results for LYT-200 in Relapsed/Refractory (R/R) High-Risk Myelodysplastic Syndromes (HR-MDS) and Acute Myeloid Leukemia (AML) at ESMO 2026
2026-10-26 07:00 · Yahoo
PureTech Announces Presentation of Phase 1b Results for LYT-200 in Relapsed/Refractory (R/R) High-Risk Myelodysplastic Syndromes (HR-MDS) and Acute Myeloid Leukemia (AML) at ESMO 2026
2026-10-19 06:00 · Yahoo
PureTech Founded Entity Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo™ at the 39th European College of Neuropsychopharmacology (ECNP) Congress
2026-10-09 17:00 · Yahoo
PureTech Founded Entity Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgo™ in Patients with Generalized Anxiety Disorder and Sleep Disturbance
2026-10-07 17:00 · Yahoo
PureTech Health gets Panmure Liberum ‘buy’ on value and cash returns
2026-10-07 14:00 · Yahoo
Celea Therapeutics Presents SURPASS-IPF Phase 3 Trial Design and Statistical Considerations for Evaluating Clinical Trials in Idiopathic Pulmonary Fibrosis at the IPF Summit 2026
2026-09-30 11:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.